UBS analyst Colin Bristow maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $164 to $167.
UBS Maintains Buy on Sarepta Therapeutics, Raises Price Target to $167
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.